New antiarrhythmic agents for atrial fibrillation

Autor: Conway Ds, Gregory Y.H. Lip

Publikováno v: Therapy. 1:111-121

Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in clinical practice, with an incidence that increases twofold every decade after 55 years of age. Despite recent advances in our understanding of the mechanisms of AF, effe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b7068720856b792ed9b353d975dd53a8
https://doi.org/10.2217/14750708.1.1.111

The onset presentation of multiple sclerosis differs in Hispanic/Latinx Americans compared with non-Hispanic White Americans.

Autor: Briggs FB; Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA., Conway DS; The Mellen Center for Multiple Sclerosis and Research, Department of Neurology, Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA., Hersh CM; Lou Ruvo Center for Brain Health, Cleveland Clinic Foundation, Las Vegas, NV, USA., Fitzgerald KC; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Mowry E; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Cohen JA; The Mellen Center for Multiple Sclerosis and Research, Department of Neurology, Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA., Ontaneda D; The Mellen Center for Multiple Sclerosis and Research, Department of Neurology, Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.

Publikováno v: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2024 Dec 24, pp. 13524585241304976. Date of Electronic Publication: 2024 Dec 24.

Cyrene™ as a green alternative to N , N '-dimethylformamide (DMF) in the synthesis of MLCT-emissive ruthenium(II) polypyridyl complexes for biological applications.

Autor: James SD; Department of Chemistry, Faculty of Science and Engineering, Swansea University, Swansea, UK. m.r.gill@swansea.ac.uk., Elgar CE; Department of Chemistry, Faculty of Science and Engineering, Swansea University, Swansea, UK. m.r.gill@swansea.ac.uk., Chen D; State Key Laboratory of Biotherapy, Department of Radiology and National Clinical Research Center for Geriatrics, Huaxi MR Research Center (HMRRC), Frontiers Science Center for Disease-Related Molecular Network, West China Hospital of Sichuan University, Sichuan University, Chengdu 610000, Sichuan Province, China. xiaohe.t@wchscu.cn., Lewis MI; Department of Chemistry, Faculty of Science and Engineering, Swansea University, Swansea, UK. m.r.gill@swansea.ac.uk., Ash ETL; Department of Chemistry, Faculty of Science and Engineering, Swansea University, Swansea, UK. m.r.gill@swansea.ac.uk., Conway DS; Department of Chemistry, Faculty of Science and Engineering, Swansea University, Swansea, UK. m.r.gill@swansea.ac.uk., Tuckley BJ; Department of Chemistry, Faculty of Science and Engineering, Swansea University, Swansea, UK. m.r.gill@swansea.ac.uk., Phillips LE; Department of Chemistry, Faculty of Science and Engineering, Swansea University, Swansea, UK. m.r.gill@swansea.ac.uk., Kolozsvári N; Department of Chemistry, Faculty of Science and Engineering, Swansea University, Swansea, UK. m.r.gill@swansea.ac.uk., Tian X; State Key Laboratory of Biotherapy, Department of Radiology and National Clinical Research Center for Geriatrics, Huaxi MR Research Center (HMRRC), Frontiers Science Center for Disease-Related Molecular Network, West China Hospital of Sichuan University, Sichuan University, Chengdu 610000, Sichuan Province, China. xiaohe.t@wchscu.cn., Gill MR; Department of Chemistry, Faculty of Science and Engineering, Swansea University, Swansea, UK. m.r.gill@swansea.ac.uk.

Publikováno v: Dalton transactions (Cambridge, England : 2003) [Dalton Trans] 2024 Nov 26; Vol. 53 (46), pp. 18506-18514. Date of Electronic Publication: 2024 Nov 26.

Neighborhood disadvantage, race, and clinical outcomes in neuromyelitis optica spectrum disorder.

Autor: Abbatemarco JR; Mellen Center for Multiple Sclerosis, Cleveland Clinic Foundation, Cleveland, OH, USA., Aboseif A; Mellen Center for Multiple Sclerosis, Cleveland Clinic Foundation, Cleveland, OH, USA.; Center for Multiple Sclerosis and Autoimmune Neurology, Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA., Swetlik C; Mellen Center for Multiple Sclerosis, Cleveland Clinic Foundation, Cleveland, OH, USA., Widmar J; Mellen Center for Multiple Sclerosis, Cleveland Clinic Foundation, Cleveland, OH, USA., Harvey T; Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, USA., Kunchok A; Mellen Center for Multiple Sclerosis, Cleveland Clinic Foundation, Cleveland, OH, USA., O'Mahony J; Mellen Center for Multiple Sclerosis, Cleveland Clinic Foundation, Cleveland, OH, USA., Miller DM; Mellen Center for Multiple Sclerosis, Cleveland Clinic Foundation, Cleveland, OH, USA., Conway DS; Mellen Center for Multiple Sclerosis, Cleveland Clinic Foundation, Cleveland, OH, USA.

Publikováno v: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2024 Sep; Vol. 30 (10), pp. 1322-1330. Date of Electronic Publication: 2024 Aug 06.

The patient-reported wearing-off phenomenon with monoclonal antibody treatments for multiple sclerosis.

Autor: Marian LM; Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH, USA., Harris KA; Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH, USA., Conway DS; Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH, USA.

Publikováno v: Multiple sclerosis journal - experimental, translational and clinical [Mult Scler J Exp Transl Clin] 2024 May 06; Vol. 10 (2), pp. 20552173241251707. Date of Electronic Publication: 2024 May 06 (Print Publication: 2024).